Protein drugs are notoriously difficult to deliver orally – but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.
A new biotech incubator, which will be located at CSL’s new Global Headquarters in Melbourne, Australia, is welcoming expressions of interest ahead of its 2024 launch.
BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.
Almost all of Australia’s vaccines are imported: creating a potential crisis in a pandemic. As a result, the country is setting out its strategy for developing vaccine manufacturing capabilities.
Pfizer is set to acquire Australia’s ResApp - a company developing a smartphone app to detect COVID-19 and other respiratory diseases based on the user’s cough - for $100m AUD ($74m USD).
Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.
Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.
This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.
Australian biotech EnGeneIC, which is developing its nanocell tech for use in infectious diseases (including a COVID-19 vaccine) as well as a cancer treatment, has announced a deal with US biotech ImmunityBio to develop, manufacture and commercialize...
Australian biotech researchers and entrepreneurs are being encouraged to apply for funding from the country’s first national biotech incubator, CUREator.
Moderna has signed a Memorandum of Understanding with the government of Canada to build a mRNA vaccine manufacturing facility in the country: which could serve as a model for similar partnerships around the world.
Thanks in part to swift COVID-19 response and relatively low infection rates, more sites and sponsors are looking at the region to locate their studies.
Moderna has agreed to provide 15m doses of its updated variant COVID-19 vaccine to Australia, providing a boost to its efforts to generate ongoing revenues from its coronavirus work.
Australia’s Therapeutic Goods Administration (TGA) has approved manufacture of the AstraZeneca COVID-19 vaccine by CSL – Seqirus: reducing the country's dependence on limited supply from abroad and allowing a wider vaccination campaign to begin....
Australia’s Therapeutics Goods Administration (TGA) has provisionally approved the Pfizer/BioNTech COVID-19 vaccine: making it the first available in the country.
Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.
Potential vaccines for COVID-19 should not be affected by changes in SARS-CoV-2 seen to date, nor are they likely to need to be redeveloped seasonally, according to Australian scientists.
Venom from honeybees has been found to rapidly destroy triple-negative breast cancer and HER2-enriched breast cancer cells – with minimal effect on healthy cells, according to a study published this month.
The Australian Government has made a $1.7bn AUD ($1.24bn USD) supply and production agreement for COVID-19 vaccines: with the first doses set to come from AstraZeneca’s vaccine in January 2021.
Operations will continue and may even be enhanced at DSM’s Australian taxpayer-funded biologics plant following a merger with Patheon, the Queensland Government says.
Royal DSM has confirmed that its biologics manufacturing operations and new Australian facility will be part of the business merged with Patheon in its agreement with JLL.
DSM says its new biomanufacturing facility will benefit the Australian biotech sector, overcoming the problems of distance with foreign contract manufacturers.
With backing from the Australian Government, DSM has opened a mammalian cell culture operation to fuel the growing demand in the Asia-Pacific biologics market.
